Beihai Kangcheng cooperates with apogenix in the development of new GBM monoclonal antibody apg-101

On July 15, 2015 Beijing time, Beihai Kangcheng (Beijing) Pharmaceutical Technology Co., Ltd (hereinafter referred to as "Beihai Kangcheng") and apogenix GmbH of Germany (hereinafter referred to as "apogenix") jointly announced that they had signed an exclusive R & D, production and marketing agreement in China for the targeted monoclonal antibody apg101 for the treatment of glioblastoma According to the terms of the agreement, Hokkaido Kangcheng has the exclusive right to develop, manufacture and market apg-101, a targeted monoclonal antibody for the treatment of glioblastoma (or other indications), in mainland China, Macao and Hong Kong Apg-101 is an innovative biological targeting drug targeting on CD95 ligand It has a unique dual action mechanism, which can restore immune function and effectively inhibit the growth of tumor cells In the phase II clinical trials that have been carried out in Europe, apg-101 has reached the main study end point for patients with malignant glioblastoma who fail in the first-line treatment, significantly prolonging the progression free survival period and the total survival period, while showing good safety In Europe, another clinical trial of apg-101 in myelodysplastic syndrome (MDS) has entered phase I According to the terms of the agreement, apogenix will gradually receive the project down payment, milestone achievement payment, in addition to the commission income which may reach up to double-digit percentage according to the future sales performance As the international scientific and technological cooperation base of Beijing for tumor cutting-edge diagnosis and treatment, Beihai Kangcheng is committed to introducing and developing innovative pharmaceutical products urgently needed in clinical practice The company has officially launched the project of "brain glioblastoma targeted monoclonal antibody drug can008 and associated diagnosis research, development and industrialization", officially entered the first clinical research of can008 in July, and launched the industrialization platform of monoclonal antibody fusion protein technology in the third quarter of next year "At present, there are few choices for the treatment of glioblastoma in clinic The first-line treatment is the combination of temozolomide and radiotherapy, and its therapeutic effect can not meet the clinical needs New drugs for glioblastoma are urgently needed It is hoped that apg101 will perform well in future clinical trials Professor Mao Ying of Huashan Hospital Affiliated to Fudan University, a famous neurosurgeon expert in China, commented As for glioblastoma, glioblastoma (GBM) is one of the tumors with the highest mortality rate and the most unfavorable prognosis The 5-year mortality rate is the third only after pancreatic cancer and lung cancer At present, the guideline of molecular diagnosis and treatment of gliomas in China suggests that GBM should be treated by surgery and / or radiotherapy and / or chemotherapy The current standard treatment has not reached the level of individualized treatment The median overall survival time was less than 15 months, the 1-year survival rate was 18%, and the 2-year survival rate was only 3% In 2014, the incidence rate of malignant glioblastoma in 1.75 of China was 1.75, and it is expected to increase to 2.05 by 2024 On December 3, 2014, Beihai Kangcheng (Beijing) Pharmaceutical Technology Co., Ltd announced the conclusion of round a financing agreement The leading investment institution is Qiming venture partners, in addition to Taifu capital and other institutions established by Taige pharmaceutical, with an investment scale of US $10 million Beihai Kangcheng is committed to the later development and listing of innovative drugs The company was founded in 2012 by Xue Qun, an executive of Genzyme Corporation and an expert of Beijing Haiju engineering, with its headquarters in Beijing Through its own unique resources and qualifications, the company has acquired, developed and listed biomedical technologies and achievements that can significantly solve the serious health problems of Chinese and Asian people, and completed the research and development of pharmaceutical products with independent intellectual property rights through technological transformation and re innovation As an international scientific and technological cooperation base of tumor frontier diagnosis and treatment certified by Beijing Municipal Science and Technology Commission, Beihai Kangcheng has carried out or talked about technical cooperation in the field of anticancer drugs with a number of European and American innovative biopharmaceutical companies and research institutions Among them, EUSA Pharma, a subsidiary of jazz pharmaceuticals, signed the exclusive listing agreement of caphosol ® in China; and azaya therapeutics signed the agreement on the cooperative research and development and listing of anti lung cancer new drug ati-1123 in China and North Asia market About Beihai Kangcheng Beihai Kangcheng is an innovative pharmaceutical technology enterprise headquartered in Beijing, China By connecting the world's largest life high-tech pharmaceutical product line with the world's fastest-growing and potential application market, we can accelerate the marketization of high-end and special effect pharmaceutical products in China and Asia The chief consultant of the company is Mr Henry Tamil, the former chairman and CEO of Genzyme Mr Tamil is recognized as a pioneer in the field of developing and providing treatment solutions for patients with rare genetic diseases around the world, and one of the founders of the global biopharmaceutical industry The core competitiveness of Beihai Kangcheng is not only reflected in the world-class consultants and management teams, but also compared with other enterprises in the same industry, the ability of Beihai Kangcheng to select, evaluate and obtain high-quality projects, the ability of project implementation and management, and the scientific research capacity of clinical development all show its superior advantages For more information, please visit